246 related articles for article (PubMed ID: 29671345)
1. A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
Yang S; Ambrosius WT; Fine LJ; Bress AP; Cushman WC; Raj DS; Rehman S; Tamariz L
Clin Trials; 2018 Jun; 15(3):305-312. PubMed ID: 29671345
[TBL] [Abstract][Full Text] [Related]
2. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
[TBL] [Abstract][Full Text] [Related]
3. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
4. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
Rauch G; Brannath W; Brückner M; Kieser M
Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
[TBL] [Abstract][Full Text] [Related]
5. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
6. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
7. Improving testing and description of treatment effect in clinical trials with survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):530-544. PubMed ID: 29671899
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
9. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
10. Sequential tests for non-proportional hazards data.
Brückner M; Brannath W
Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
[TBL] [Abstract][Full Text] [Related]
11. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
[TBL] [Abstract][Full Text] [Related]
12. Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week.
Gregson J; Sharples L; Stone GW; Burman CF; Öhrn F; Pocock S
J Am Coll Cardiol; 2019 Oct; 74(16):2102-2112. PubMed ID: 31623769
[TBL] [Abstract][Full Text] [Related]
13. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
[TBL] [Abstract][Full Text] [Related]
14. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
15. How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?
Horiguchi M; Hassett MJ; Uno H
Oncologist; 2019 Jul; 24(7):867-871. PubMed ID: 30201741
[TBL] [Abstract][Full Text] [Related]
16. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
17. Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards.
Möllenhoff K; Tresch A
Lifetime Data Anal; 2023 Jul; 29(3):483-507. PubMed ID: 36708450
[TBL] [Abstract][Full Text] [Related]
18. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
19. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
20. Analysis of time to event outcomes in randomized controlled trials by generalized additive models.
Argyropoulos C; Unruh ML
PLoS One; 2015; 10(4):e0123784. PubMed ID: 25906075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
